Note 7 - Stockholders' Equity	9 Months Ended
Mar. 31, 2023
Notes to Financial Statements
Shareholders' Equity and Share-Based Payments [Text Block]	NOTE 7. STOCKHOLDERS’ EQUITY Payment of cash dividends is within the discretion of the Company’s Board of Directors and is dependent on earnings, operations, capital requirements, general financial condition of the Company, and general business conditions. The dividend rate per share was $0.0050 per month for July 2021 through September 2021, and $0.0075 per month for October 2021 through March 2023. In March 2023, the Board authorized the continuance of the monthly dividend of $0.0075 per share from April through June 2023, at which time it will be considered for continuation by the Board. The Company has a share repurchase program, approved by the Board of Directors, authorizing the Company to annually purchase up to $5.0 million of its outstanding common shares, as market and business conditions warrant, on the open market in compliance with Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934. The repurchase program has been in place since December 2012, and the Board of Directors has annually renewed the repurchase program each calendar year. The Company announced on February 25, 2022, that the Board of Directors of the Company approved an increase to the limit of its annual share buyback program from $2.75 million to $5.0 million. The acquired shares may be used for corporate purposes, including shares issued to employees in the Company’s stock-based compensation programs. For the three and nine months ended March 31, 2023, the Company repurchased 193,040 and 320,412 class A shares using cash of $556,000 and $938,000, respectively. For the three and nine months ended March 31, 2022, the Company repurchased 19,487 and 43,591 class A shares using cash of $97,000 and $233,000, respectively. The Company’s stock option plans provide for the granting of class A shares as either incentive or nonqualified stock options to employees and non-employee directors. Options are subject to terms and conditions determined by the Compensation Committee of the Board of Directors. At March 31, 2023, there were 229,000 options outstanding and exercisable under the 1989 Plan at a weighted average exercise price of $6.05, and 2,000 options outstanding and exercisable under the 1997 Plan at a weighted average exercise price of $2.74. At March 31, 2022, there were 231,000 options outstanding and exercisable under the 1989 Plan at a weighted average exercise price of $6.05, and 2,000 options outstanding and exercisable under the 1997 Plan at a weighted average exercise price of $2.74. There were no options granted or exercised for the three and nine months ended March 31, 2023, or 2022. There were 2,000 options forfeited during the nine months ended March 31, 2023, and no options forfeited during the three months ended March 31, 2023, or the three and nine months ended March 31, 2022. Stock-based compensation expense is measured at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the award’s vesting period. There was no stock-based compensation expense for the three and nine months ended March 31, 2023, or for the three months ended March 31, 2022. For the nine months ended March 31, 2022, $733,000 was recognized as expense on the consolidated statements of operations. As of March 31, 2023, and 2022, there was no unrecognized share-based compensation cost related to share-based awards granted under the plans.

Note 7 - Stockholders' Equity

9 Months Ended

Mar. 31, 2023

Shareholders' Equity and Share-Based Payments [Text Block]

NOTE 7. STOCKHOLDERS’ EQUITY

Payment of cash dividends is within the discretion of the Company’s Board of Directors and is dependent on earnings, operations, capital requirements, general financial condition of the Company, and general business conditions. The dividend rate per share was $0.0050 per month for July 2021 through September 2021, and $0.0075 per month for October 2021 through March 2023.

In March 2023, the Board authorized the continuance of the monthly dividend of $0.0075 per share from April through June 2023, at which time it will be considered for continuation by the Board.

The Company has a share repurchase program, approved by the Board of Directors, authorizing the Company to annually purchase up to $5.0 million of its outstanding common shares, as market and business conditions warrant, on the open market in compliance with Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934. The repurchase program has been in place since December 2012, and the Board of Directors has annually renewed the repurchase program each calendar year. The Company announced on February 25, 2022, that the Board of Directors of the Company approved an increase to the limit of its annual share buyback program from $2.75 million to $5.0 million. The acquired shares may be used for corporate purposes, including shares issued to employees in the Company’s stock-based compensation programs. For the three and nine months ended March 31, 2023, the Company repurchased 193,040 and 320,412 class A shares using cash of $556,000 and $938,000, respectively. For the three and nine months ended March 31, 2022, the Company repurchased 19,487 and 43,591 class A shares using cash of $97,000 and $233,000, respectively.

The Company’s stock option plans provide for the granting of class A shares as either incentive or nonqualified stock options to employees and non-employee directors. Options are subject to terms and conditions determined by the Compensation Committee of the Board of Directors. At March 31, 2023, there were 229,000 options outstanding and exercisable under the 1989 Plan at a weighted average exercise price of $6.05, and 2,000 options outstanding and exercisable under the 1997 Plan at a weighted average exercise price of $2.74. At March 31, 2022, there were 231,000 options outstanding and exercisable under the 1989 Plan at a weighted average exercise price of $6.05, and 2,000 options outstanding and exercisable under the 1997 Plan at a weighted average exercise price of $2.74. There were no options granted or exercised for the three and nine months ended March 31, 2023, or 2022. There were 2,000 options forfeited during the nine months ended March 31, 2023, and no options forfeited during the three months ended March 31, 2023, or the three and nine months ended March 31, 2022.

Stock-based compensation expense is measured at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the award’s vesting period. There was no stock-based compensation expense for the three and nine months ended March 31, 2023, or for the three months ended March 31, 2022. For the nine months ended March 31, 2022, $733,000 was recognized as expense on the consolidated statements of operations. As of March 31, 2023, and 2022, there was no unrecognized share-based compensation cost related to share-based awards granted under the plans.